Research Article
Improved Efficacy of Transcatheter Arterial Chemoembolization Using Warmed Miriplatin for Hepatocellular Carcinoma
Table 2
Results of logistic regression analysis.
| Factors | Odds ratio (95% CI) | P value |
| Sex (female) | 0.39 (0.12–1.17) | 0.10 | HBV infection | 0.30 (0.046–1.49) | 0.16 | Tumor size (mm2) | 1.00 (1.00-1.00) | 0.13 | AFP (ng/mL) | 1.00 (1.00-1.00) | 0.16 | DCP (mAU/mL) | 1.00 (1.00-1.00) | 0.14 | BCLC stage C | 0.77 (0.24–2.43) | 0.66 | BCLC stage D | 36.55 (0.70–3635.77) | 0.078 | History of TACE | 0.78 (0.27–2.24) | 0.64 | Warming miriplatin | 12.35 (2.90–90.0) | 0.0028** | Miriplatin dose (mg) | 0.99 (0.96–1.01) | 0.43 | Severe hepatic arterial damage | 0.59 (0.10–2.73) | 0.52 |
|
|
. CI: confidence interval; HBV: hepatitis B virus; AFP: alpha-fetoprotein; DCP: des-gamma-carboxyprothrombin; BCLC: Barcelona Clinic Liver Cancer; TACE: transcatheter arterial chemoembolization.
|